More and more pharma companies are looking "beyond the pill" when it comes to providing care for patients, few more so than Eisai, which is developing a package of products and services in Japan ...

With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker is counting on its 2027 fiscal year to be a blockbuster year for the drug | ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug. Tasfygo (tasurgratinib succinate; formerly E7090), a small-molecule ...

For centuries, residents in central Japan have chronicled a mysterious natural phenomenon in winter. They see its ...

Eisai shares fell sharply after its Alzheimer ... Lecanemab is already approved in the U.S., Japan, China and other countries. Considering the dim view the committee has of the drug’s safety ...

TOKYO, Mar 5, 2025 - (JCN Newswire) - Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan ...

and consumer healthcare business in Japan, which manages over-the-counter drugs. Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the ...

Japan's Nikkei Stock Average closed 0.3% higher at 35725.87 as gains in the heavy industry and video game shares offset the ...

DE&I (Diversity, Equity & Inclusion) is placed at the core of all human resource policies, and Eisai has been promoting women's empowerment as a first step in promoting DE&I in Japan. In 2021 ...

January 24, 2025 Merck, Eisai's combination drug fails in late-stage trial for esophageal cancer Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the ...